Key hire
Company
Theravance Biopharma
Funding history
Investors
Every investor coverage indicates participated in a round Theravance Biopharma raised.
What Theravance Biopharma bought
Companies Theravance Biopharma acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
People
| Name | Role | Sources |
|---|---|---|
| Dr Brett Haumann | Chief Medical Officer and Senior Vice President of Development (former) | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Coverage
Stories naming Theravance Biopharma. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Key hire
Aravax appoints Dr Brett Haumann to Board of Directors
Clinical-stage biotech Aravax has added pharma veteran Dr Brett Haumann, formerly of ReViral, Theravance, GSK and Aimmune, as a non-executive director ahead of a Phase 2 study of its peanut allergy therapy PVX108.